Korea Comirnaty Post-marketing Surveillance

Study Summary

This study will collect information on the safety of BNT162b2 products for subjects who have been administered in a routine clinical practice from 05Mar2021 to 04Mar2027 in Korea, and will be conducted in accordance with the New Drug Re-Examination Guideline of the Ministry of Food and Drug Safety (MFDS).

Conditions

COVID-19 Vaccines Adverse Effects SARS-CoV-2 Safety

Interventions / Drugs

Tozinameran 12 Years of age and older Tozinameran 5 to 11 Years of age Tozinameran 6 months to 4 years of age Riltozinameran 12 Years of age and older Famtozinameran 12 Years of age and older Famtozinameran 5 to 11 Years of age Raxtozinameran 12 years of age and older Raxtozinameran 6 months to 4 years of age

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment12000 participants

Primary Completion—

Lead SponsorPfizer

Data Retrieved2026-04-11 02:55:53.189666+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.